AirSculpt Technologies, Inc. (AIRS) vs Atrium Therapeutics, Inc. (RNA)
A side-by-side comparison of AirSculpt Technologies, Inc. and Atrium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AIRS
AirSculpt Technologies, Inc.
$1.89HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
RNA
Atrium Therapeutics, Inc.
$7.97HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
Total return — AIRS vs RNA
growth of $100 · dividends reinvested · last 1yAIRS +9.8% (+9.8%/yr)RNA -46.0% (-46.0%/yr)AIRS compounded faster over this window
AIRS RNA
AIRS vs RNA: by the numbers
- •RNA is the larger company ($136M vs $133M market cap).
- •Both run net losses; AIRS's is the smaller (-7.79% vs -396.52% net margin).
Metrics side by side
Valuation
| Metric | AIRS | RNA |
|---|---|---|
| P/S ratio | 0.88 | 5.81 |
| P/B ratio | 1.27 | 0.64 |
| EV / EBITDA | 434.41 | N/A |
| FCF yield | 0.57% | N/A |
Profitability
| Metric | AIRS | RNA |
|---|---|---|
| Gross margin | 57.63% | 97.90% |
| Operating margin | -7.85% | -410.23% |
| Net margin | -7.79% | -396.52% |
| ROE | -11.20% | -43.42% |
| ROIC | -7.01% | -38.45% |
Growth (annualized)
| Metric | AIRS | RNA |
|---|---|---|
| Revenue CAGR (5Y) | 8.17% | N/A |
| FCF CAGR (5Y) | -52.36% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.